Carolina Eye Associates participates in national and international clinical research studies, often referred to as clinical trials. Clinical trials allow for the scientific testing necessary to develop new and improved drugs and therapies. These studies are tightly regulated and most are controlled by the U.S. Food and Drug Administration.
In a clinical trial, new drugs and therapies are tested in a scientific way. In some trials, half of the patients receive an experimental therapy and the other half receive a placebo (a harmless pill or medicine that has no therapeutic effect). During this type of trial, neither the patient nor the doctor knows which therapy the patient has received. This is done to eliminate bias and subjectivity in the results.
Because most clinical trials require very specific clinical findings to be present in study patients, some patients are not eligible to participate in the trials. If you want more information about these trials, please contact our clinical trial coordinator, Lisa Fulghum, by emailing firstname.lastname@example.org. Our coordinator can give you additional information about the inclusion and exclusion criteria for each study.
IVANTIS – CONFIRM Study CP 18-001 – Currently Enrolling
The Hydrus® Microstent new enrollment post-approval study: A prospective, non-randomized, single arm, clinical trial for mild to moderate Primary Open-Angle Glaucoma
(Involves Cataract Surgery along with the Hydrus® Microstent)
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs – ILR431b-P001
For patients who are planning to have at least one eye implanted with an AcrySof® IQ ReSTOR Toric IOL or AcrySof® IQ ReSTOR® IOL. These IOLs are approved by the US Food and Drug Administration (FDA) and will be used according to approved product labeling during the study.
The purpose of this research is to look at intraocular inflammation after implantation of these lenses.
Bausch & Lomb 904 – Mojave Study – Currently Enrolling
A phase 3, randomized, double-masked, saline-controlled trial to evaluate the effect of NOV03 (Perfluorohexylotane) on signs and symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study)
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. – CPN-301 (Enrollment beginning soon)
A phase 3, randomized, double-masked, placebo-controlled, parallel-group study to evaluate the efficacy and safety of APP13007 for the treatment of inflammation and pain after cataract surgery
(Active ingredient: Clobetasol Propionate)